Abionyx: encouraging results in brain fog
The biotech group states that these data show that administration of CER-001 attenuated systemic inflammation and regulated indolamine-2,3-dioxygenase (IDO1), thereby reducing neuroactive metabolites and retention of residual substances.
Overall, this work indicates that treatment with CER-001 may improve renal and cognitive function in sepsis-induced acute renal failure," he adds.
From Abionyx's perspective, these preclinical data support the hypothesis that the use of CER-001 may have the potential to improve renal and cognitive function.
These findings were presented at the first international scientific congress dedicated to brain-kidney interaction, currently taking place in Naples.
Listed on the Paris Bourse, Abionyx Pharma shares climbed over 5% on Friday following these announcements.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction